In summary, because the enhancement of CD8+ T-cell activity persisted even against non-immunogenic HNSCC, PI3K p110γ inhibition may serve as a host-directed approach to bolster the anti-tumor immune response. The gene discussed is CD8A; the disease is head and neck squamous cell carcinoma.